Abstract
Context and Justification Yaws is targeted for eradication by 2030. Total Community Treatment with azithromycin (TCT), a major component of the eradication strategy, has witnessed only three pilots since 2012. We implemented the first large-scale TCT in the Congo-Basin of Central Africa using a novel model.
Methodology We implemented a novel 3-phase TCT model in 17 health districts of the Congo-Basin, spanning 3 countries. Two rounds were implemented in Cameroon, and one round each in Central African Republic (CAR) and the Republic of Congo; targeting 1,530,014 people (144,934(9.5%) Pygmies and 1,304,410(90.5%) Bantus). TCT was followed by post-campaign active surveillance, treatment of yaws cases and their contacts.
Results All 17 health districts were confirmed for yaws endemicity. Overall, 1,456,691 (95.21%; 95%CI: 95.17%-95.24%) persons were treated in the first round of TCT, including 552,356/594411 (92.92%; 95%CI: 92.86%-92.99%) in Cameroon, 359,810/373,994 (96.21%; 95%CI: 96.15%-96.27%) in CAR, and 544,526/561,609 (96.96%; 95%CI: 96.91%-97.00%) in Congo. For the second round implemented only in Cameroon, 615,503/642,947 (95.73%; 95%CI: 95.68%-95.78%) were treated. There was a 3-percentage-point increase in therapeutic coverage between the first and second round (P-value<0.001), and from 89.2% to 93.1% (P-value<0.001) among the Pygmies. The prevalence of active yaws decreased from 6.5% to 0.4% (P-value<0.001) overall; and from 6.31% to 0.23% (P-value<0.001, OR=28.67, 95%CI (20.86-40.09) in Cameroon, from 2.4% to 0.8% (P-value=0.002, OR=3.19, 95% CI: 1.45-8.00) in CAR, and from 10.8% to 3.7% (P-value<0.001, OR=3.18, 95%CI: 2.09 – 5.01) in Congo.
Conclusion A novel TCT model was successfully implemented at largescale in the Congo-Basin, achieving above recommended threshold of therapeutic coverages. The prevalence of active yaws dropped remarkably following the TCT, however complete interruption of yaws transmission was not achieved. In recommending the novel model of TCT to endemic countries, we suggest that at least three rounds, at six-monthly intervals, are implemented for complete interruption of yaws transmission.
Author summary Yaws, a skin-NTD that affects mainly children resurfaced among the Pygmies of the Congo-Basin around 2007 after eradication in the late 1970s. Renewed efforts for eradication guided by the Morges strategy are being promoted by the WHO. In this regard, we a novel model for Total Community treatment (TCT) with azithromycin in 17 health districts of the Congo-Basin spanning three countries including Cameroon, CAR and The Republic of Congo. This was the largest scale so far, since the inception of the Morges strategy. Of a total population of 1,530,014 targeted in the first round of TCT, 1,456,691(95.21%) persons were treated including 552,356 in Cameroon, 359,810 in CAR, and 544,526 in Congo. For the second implemented only in Cameroon, 615,503 (95.73%) out of 642,947 people targeted were treated. Our novel model permitted the achievement of therapeutic coverages surpassing the 90% threshold recommended by the WHO. The TCT led to a remarkable reduction of the prevalence of active yaws in the zone, but however, did not interrupt its transmission. In recommending the novel model of TCT to yaws endemic countries, we think that at least three rounds at six-monthly intervals are necessary for complete interruption of yaws transmission.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The author(s) received no specific funding for this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The intervention was approved by the Cameroon National Ethics Committee for Research in Human Health, and the Ethics Committee for Research in Health Sciences of the Republic of Congo. Administrative authorisations were also obtained from the ministries of health in the three countries involved in the intervention.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All relevant data are within the manuscript and its Supporting Information files.
